logo-loader
RNS
Bioventix

BioVentix PLC - Share Options Awarded

RNS Number : 1555B
BioVentix PLC
20 April 2026
 

Bioventix plc 

("Bioventix" or "the Company") 

Share Options Awarded

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces the award on 17 April 2026 of share options over ordinary shares in the Company (the "Options") under the Company's Share Option Plan in 2020 to the following directors, as follows:

Director

Position

Number of Options

Exercise Price

Total Number of Options held following this award

Peter Harrison

CEO

32,811

£17.75

52,622

Bruce Hiscock

CFO

9,967

£17.75

14,394

 

The Options vest between 3 and 10 years from grant and will become exercisable once the Company recognises revenue of greater than £1.0 million, as evidenced by audited financial statements prepared in accordance with UK GAAP, from a commercial diagnostic partner relating to its neurological blood test using the Company's sheep monoclonal antibody. The Options are subject to clawback and malus provisions.

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain. 

 

For further information please contact: 

Bioventix plc 

Peter Harrison 

 

Chief Executive Officer 

Tel: 01252 728 001 







Cavendish 

Geoff Nash / Elysia Bough

Nigel Birks / Harriet Ward 

 

Corporate Finance 

ECM 

Tel: 020 7220 0500 

 

 About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

 

 

The information below (set out in accordance with the requirements of UK Market Abuse Regulation) provides further detail:

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

a)    Peter Harrison

b)    Bruce Hiscock

2

Reason for the notification

a)

Position/status

a)    CEO

b)    CFO

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI


213800225MHX7LZQY108


4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each

 

GB00B4QVDF07

b)

Nature of the transaction

Issue of Options

 

c)

Price(s) and volume(s)

Exercise Price(s)

Volume(s)

£17.75

£17.75

32,811

9,967

d)

Aggregated information

- Aggregated volume

- Price

 

 

42,778

£17.75

 

e)

Date of the transaction

17 April 2026

f)

Place of the transaction

Outside a trading venue

g)

Additional Information

N/A

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFSISSIIFIR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read